The stock of Denali Therapeutics Inc (DNLI) has gone down by -4.29% for the week, with a -32.84% drop in the past month and a -37.55% drop in the past quarter. The volatility ratio for the week is 4.45%, and the volatility levels for the past 30 days are 7.52% for DNLI. The simple moving average for the last 20 days is -10.55% for DNLI stock, with a simple moving average of -38.03% for the last 200 days.
Is It Worth Investing in Denali Therapeutics Inc (NASDAQ: DNLI) Right Now?
The 36-month beta value for DNLI is also noteworthy at 1.55. There are mixed opinions on the stock, with 14 analysts rating it as a “buy,” 4 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for DNLI is 125.71M, and at present, short sellers hold a 7.07% of that float. The average trading volume of DNLI on March 21, 2025 was 1.04M shares.
DNLI) stock’s latest price update
Denali Therapeutics Inc (NASDAQ: DNLI)’s stock price has decreased by -0.75 compared to its previous closing price of 14.61. However, the company has seen a -4.29% decrease in its stock price over the last five trading sessions. seekingalpha.com reported 2025-03-20 that Denali Therapeutics’ stock has significantly dropped from $100 to $15 since 2021, but the company is now heavily derisked with promising product candidates nearing key milestones. Lead asset DNL310 shows strong biomarker data for Hunter syndrome, with plans for a BLA submission and accelerated approval by Q2 2025. The Biogen partnership for Parkinson’s Disease asset DNL151 includes substantial milestone payments and profit-sharing, highlighting its potential impact.
Analysts’ Opinion of DNLI
Many brokerage firms have already submitted their reports for DNLI stocks, with Morgan Stanley repeating the rating for DNLI by listing it as a “Overweight.” The predicted price for DNLI in the upcoming period, according to Morgan Stanley is $33 based on the research report published on March 07, 2025 of the current year 2025.
Deutsche Bank, on the other hand, stated in their research note that they expect to see DNLI reach a price target of $31. The rating they have provided for DNLI stocks is “Buy” according to the report published on February 11th, 2025.
Robert W. Baird gave a rating of “Outperform” to DNLI, setting the target price at $31 in the report published on January 07th of the current year.
DNLI Trading at -26.12% from the 50-Day Moving Average
After a stumble in the market that brought DNLI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -56.50% of loss for the given period.
Volatility was left at 7.52%, however, over the last 30 days, the volatility rate increased by 4.45%, as shares sank -30.15% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -31.63% lower at present.
During the last 5 trading sessions, DNLI fell by -4.42%, which changed the moving average for the period of 200-days by -28.95% in comparison to the 20-day moving average, which settled at $16.21. In addition, Denali Therapeutics Inc saw -28.85% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DNLI starting from Ho Carole, who sale 12,255 shares at the price of $20.22 back on Jan 06 ’25. After this action, Ho Carole now owns 178,580 shares of Denali Therapeutics Inc, valued at $247,796 using the latest closing price.
Ho Carole, the Chief Medical Officer of Denali Therapeutics Inc, sale 2,907 shares at $20.81 during a trade that took place back on Jan 07 ’25, which means that Ho Carole is holding 175,673 shares at $60,495 based on the most recent closing price.
Stock Fundamentals for DNLI
The total capital return value is set at -0.39. Equity return is now at value -37.40, with -33.45 for asset returns.
Based on Denali Therapeutics Inc (DNLI), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -7.14.
Currently, EBITDA for the company is -487.34 million with net debt to EBITDA at 0.26. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.46.
Conclusion
In summary, Denali Therapeutics Inc (DNLI) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
